One inflation, one dose — no permanent implant left behind
Drug-coated balloon (DCB) angioplasty delivers a single local dose of an antiproliferative drug during one brief balloon inflation, without leaving any permanent metal or polymer scaffold behind. A catheter carrying a crystalline drug formulation bonded to the balloon surface via a fast-dissolving excipient is threaded to the lesion — frequently a small-caliber vessel, an in-stent restenosis (ISR) segment, or a location where a second permanent stent would be undesirable.
A drug-eluting stent (DES) achieves durable antiproliferative drug delivery by permanently caging the vessel wall with a metal scaffold and polymer drug reservoir. That permanence is exactly what several clinical scenarios want to avoid:
• Small vessels (<3 mm): metal struts occupy proportionally more luminal area, raising late lumen loss and restenosis risk; a permanent foreign body in a small caliber vessel is mechanically disadvantageous • In-stent restenosis (ISR): the vessel already contains one (or more) stent layers — adding another creates a multi-layered metal cage ("stent-on-stent") that further compromises vessel compliance and future revascularization options • High bleeding-risk patients: a permanent stent mandates prolonged dual antiplatelet therapy (DAPT, typically 6–12 months) to prevent stent thrombosis; DCB-only treatment allows much shorter antiplatelet courses since there is no metal surface requiring endothelialization • Bifurcation side branches: placing a stent across a branch point risks jailing or compromising the side branch ostium; a DCB can treat the branch without altering its geometry permanently
The unifying rationale is that the therapeutic goal — suppressing neointimal proliferation — does not require a permanent implant. If a single, brief, local drug dose can achieve durable suppression, the permanent scaffold becomes an avoidable liability rather than a necessity.
DCB therapy separates two things angioplasty historically bundled together: mechanical scaffolding (keeping the vessel open) and pharmacologic control of restenosis (paclitaxel suppressing smooth-muscle proliferation). DCB provides only the second — a "vascular brachytherapy without radiation."
DCB angioplasty has accumulated the strongest evidence in three settings:
• Femoropopliteal peripheral artery disease: the superficial femoral artery is long, subject to high mechanical stress (torsion, compression, flexion) that can fracture rigid stents; DCBs avoid placing a rigid structure across a joint-adjacent segment. Landmark trials (IN.PACT SFA, LEVANT 2) showed primary patency around 78–82% at 12 months for DCB versus ~50–55% for plain balloon angioplasty (POBA) • Coronary in-stent restenosis: treating ISR with another DES creates progressively thicker multilayer metal; DCB avoids this while achieving comparable angiographic outcomes to repeat DES in several head-to-head trials (RIBS IV, ISAR-DESIRE 3) • Small coronary vessels: trials such as BASKET-SMALL 2 demonstrated DCB non-inferiority to DES for vessels ≤2.75 mm at lower long-term cost and shorter DAPT exposure
Lesion preparation matters: adequate predilation (often with a standard or scoring/cutting balloon) to crack calcific plaque and optimize luminal gain is typically performed before the DCB is deployed, since drug transfer efficiency depends heavily on achieving full wall apposition in the next stage.
Drug transfer from a DCB is a contact-mediated process — the coated balloon membrane must physically touch the arterial wall for the crystalline drug to release and cross into tissue. Achieving full, uniform circumferential apposition during the brief inflation window is therefore as important to outcome as the coating formulation itself.
The balloon is advanced over a guidewire to the lesion and inflated with a dilute contrast/saline mixture using an inflation device that reads pressure directly in atmospheres. Pressure is raised steadily to the operator-selected level — typically the "nominal" pressure printed on the balloon's compliance chart, occasionally higher for resistant or calcific lesions, always kept below the balloon's rated burst pressure.
As the balloon expands, its coated outer membrane presses radially outward until it meets the arterial wall along its entire treated length. Full apposition requires:
• Correct balloon sizing relative to reference vessel diameter (typically sized 1:1, occasionally slightly undersized to reduce dissection risk while still achieving adequate contact) • Adequate lesion preparation (predilation) so the balloon can fully expand against plaque rather than being constrained by an undilated, non-compliant segment • Sufficient dwell pressure and time for the semi-compliant balloon material to conform to wall irregularities
Incomplete apposition — from residual stenosis, spiral dissection flaps, or heavy calcification that resists full balloon expansion — leaves gaps where the coated surface never contacts tissue, and drug in those gaps is simply lost to the bloodstream instead of being absorbed.
Higher inflation pressure improves apposition but also raises the risk of vessel injury — dissection, elastic recoil, or perforation in fragile or heavily diseased segments. Operators balance:
• Nominal pressure: the pressure at which the balloon reaches its labeled diameter with predictable, compliant behavior • Rated burst pressure (RBP): the pressure below which balloon rupture is statistically very unlikely (usually specified with 99.9% confidence) • Dwell time: DCB protocols generally recommend longer inflation than a plain balloon (often 30–180 seconds depending on vessel bed and device) specifically to allow drug transfer to occur while apposition is maintained, rather than the brief 10–20 second inflations sometimes used for simple mechanical dilation
Because the inflation itself briefly occludes flow distal to the balloon, operators must also weigh ischemic tolerance of the downstream territory (particularly relevant in coronary arteries) against the benefit of a longer dwell time for more complete drug transfer.
Within the same 30–90 second inflation used for mechanical dilation, the coating must dissolve, release its crystalline drug, and drive that drug across the endothelium and into the media — an extraordinarily fast pharmacokinetic event compared to the days-to-weeks elution profile of a drug-eluting stent polymer.
Paclitaxel itself is essentially insoluble in water and, in its pure crystalline form bonded directly to a balloon, would transfer to tissue far too slowly to be useful in a single short inflation. The engineering solution is a hydrophilic excipient — a small, fast-dissolving "spacer" molecule co-formulated with the crystalline drug on the balloon surface:
• Iopromide-based coatings (used in several first-generation DCBs) rely on a contrast-agent-derived excipient that rapidly solubilizes on contact with blood and tissue fluid • Urea-based and other low-molecular-weight hydrophilic carriers serve a similar spacer role in other device platforms • Shellac, polysorbate, and various proprietary amphiphilic excipients are used across different commercial coatings, each tuned for a particular balance of coating adherence during delivery (so drug is not washed off in transit through the vasculature) versus rapid release on balloon contact with the lesion
The excipient performs two jobs simultaneously: it keeps the crystalline drug firmly bonded to the balloon during the trip from the groin or wrist access site to the lesion (avoiding premature loss into systemic circulation), and then dissolves almost instantly once the balloon is inflated against the wall — freeing the crystalline paclitaxel to embed directly into the tissue rather than remaining trapped in a slow-release matrix.
Because paclitaxel is highly lipophilic, once it crosses into the arterial wall it partitions strongly into cell membranes and lipid-rich tissue rather than washing back out into the bloodstream — this is what allows a transfer event lasting under a minute to produce a drug depot that persists for weeks.
The transfer process unfolds in three overlapping phases during the single inflation:
1. Dissolution (first few seconds): blood and interstitial fluid contact the coating; the hydrophilic excipient rapidly solubilizes, releasing crystalline drug particles from the balloon surface
2. Diffusive/convective uptake (through the remainder of the dwell time): freed drug crystals and dissolved drug molecules move across the endothelium, driven by the concentration gradient and by the mechanical pressure of the inflated balloon against the wall, which favors local uptake over systemic washout
3. Tissue binding (continuing after balloon removal): once in the media, paclitaxel binds tubulin and partitions into lipid membranes, effectively trapping a fraction of the delivered dose locally rather than allowing it to diffuse back into the lumen
Only a minority of the nominal coated dose (commonly cited estimates are roughly 10–20%, device-dependent) is actually retained in the arterial wall — the remainder is lost to the bloodstream during delivery, deflation, and withdrawal, or washed away by flow before binding. Coating dose, dwell time, and apposition quality are the three levers that determine how much of that theoretical dose becomes real tissue concentration.
The balloon is deflated and removed exactly as it arrived — through the existing arterial access — leaving the vessel anatomically as it was before treatment except for the drug now embedded in the wall. No metal, no polymer, and no permanent geometry change remain in the artery.
DCB and DES both suppress restenosis pharmacologically, but they differ fundamentally in how the drug is delivered and what — if anything — remains afterward:
• Mechanism: DES elutes drug slowly from a polymer reservoir over weeks to months while the metal scaffold provides continuous mechanical support; DCB delivers a single high-concentration local dose in under two minutes with no ongoing scaffold • Mechanical support: DES structurally props the vessel open, useful for lesions prone to elastic recoil or dissection; DCB provides none, so it depends on the vessel holding its own shape after treatment (aided by adequate lesion preparation) • Antiplatelet burden: DES requires prolonged DAPT to cover the metal surface until endothelialization is complete; DCB-only treatment typically needs only a short antiplatelet course, benefiting patients at high bleeding risk or those needing surgery soon after • Repeat revascularization: a vessel with no implanted metal is easier to re-treat surgically or endovascularily in the future; layered stents progressively narrow future options • Failure mode: DES failure can involve late/very-late stent thrombosis tied to the permanent foreign surface; DCB failure is typically recoil or dissection at the time of the original procedure, addressed immediately with provisional (bailout) stenting if needed
Neither approach is universally superior — the choice depends on vessel size, lesion morphology, restenosis history, and bleeding risk, which is why DCB has become established as the treatment of choice for specific niches rather than a wholesale DES replacement.
Provisional bailout stenting — placing a stent only if the vessel shows flow-limiting dissection or unacceptable recoil after DCB treatment — is the standard safety net in DCB protocols, occurring in roughly 5–15% of cases depending on vessel bed and lesion complexity.
Removing the permanent scaffold from the treatment equation has downstream effects beyond the index procedure:
• Shortened antiplatelet therapy directly reduces bleeding complications, which matters most for patients who are elderly, have upcoming surgery, or have a history of GI or intracranial bleeding • Preserved vessel compliance matters in mobile anatomic segments (femoropopliteal artery crossing the knee) where a rigid stent is subject to fatigue fracture from repeated flexion and torsion • Unobstructed future access means a patient who eventually needs bypass surgery, repeat angioplasty, or even DES placement at the same site is not working around pre-existing layered metal • No permanent nidus for restenosis or thrombosis — restenosis after DCB, when it occurs, tends to behave like recurrent native disease rather than the neoatherosclerosis seen inside old stent struts
These properties are precisely why DCB angioplasty is positioned as the default choice in the specific clinical situations described in Stage 1 (small vessels, ISR, high bleeding risk, bifurcations) rather than as a general-purpose alternative to DES everywhere.
The most counterintuitive part of DCB pharmacology is that a drug exposure lasting under two minutes produces a biological effect lasting weeks to months — comparable to the sustained release from a drug-eluting stent, but achieved with a single local depot rather than continuous elution.
Paclitaxel's antiproliferative action does not require continuous re-dosing because of how it interacts with its cellular target:
• Tubulin binding: paclitaxel stabilizes microtubules, locking the cytoskeletal machinery smooth-muscle cells need to divide. A cell exposed to enough paclitaxel is arrested in the cell cycle essentially permanently for that cell, not just for as long as drug concentration is elevated • Lipophilic tissue retention: because paclitaxel partitions into lipid membranes and binds cellular structures rather than remaining freely dissolved, it resists being washed back into the bloodstream once it has crossed into the arterial wall — the single-dose depot degrades and clears slowly over weeks rather than being cleared like a freely soluble drug • Timing alignment: neointimal proliferation — the process DCB and DES both aim to blunt — peaks in the weeks following any vessel injury (angioplasty itself triggers a wound-healing/proliferative response). A drug depot that persists through that proliferative window is pharmacologically sufficient even without ongoing elution, because the vulnerable period for restenosis is itself finite
The net effect is that a single, brief, high local concentration achieves what a slow-release stent achieves with continuous low-level elution — both strategies are simply covering the same several-week biological window by different delivery mechanics.
Pivotal peripheral trials such as IN.PACT SFA reported roughly 82% primary patency at 12 months for paclitaxel DCB versus about 52% for plain balloon angioplasty alone — a durable difference attributable entirely to a treatment event that took place in under three minutes.
DCB technology has matured across three principal application areas, each with a distinct evidence base:
• Femoropopliteal peripheral arterial disease: the largest and most mature DCB evidence base, with multiple randomized trials (IN.PACT SFA, LEVANT 2, ILLUMENATE) consistently showing superior patency over plain balloon angioplasty in claudicant and, increasingly, more complex lesions • Coronary in-stent restenosis: DCB is now a guideline-supported option for both bare-metal and drug-eluting stent ISR, avoiding the metal-on-metal layering that repeat stenting would create, with angiographic outcomes comparable to repeat DES in several trials • Small coronary vessels: growing evidence (BASKET-SMALL 2 and others) supports DCB as non-inferior to DES in vessels too small to reliably accommodate a stent without disproportionate luminal compromise, while avoiding the long DAPT requirement
Ongoing research is extending DCB technology to below-the-knee peripheral disease, coronary bifurcation side branches, and de novo (never-stented) coronary lesions more broadly — areas where the "leave nothing behind" principle may extend DCB's current niche role into a larger share of everyday interventional practice.